Literature DB >> 17495526

Cell cycle regulation targets of MYCN identified by gene expression microarrays.

Emma Bell1, John Lunec, Deborah A Tweddle.   

Abstract

BACKGROUND: We have previously shown that MYCN knockdown causes a G1 arrest in MYCN amplified (MNA), p53 wild type (wt) and p53 mutant MNA neuroblastoma cell lines, with increases in p21(WAF1) and hypo RB in p53 wt cell lines. HYPOTHESIS: MYCN acts by inhibiting p21(WAF1), and also by p21(WAF1) independent mechanisms to override the G1 checkpoint in exponentially growing cells.
METHODS: Genes potentially regulated by MYCN were identified using gene expression microarrays in p53 wt MNA IMR-32 and p53 mutant MNA SKNBE(2c) neuroblastoma cell lines treated with MYCN or scrambled siRNA. Results were validated using qRT-PCR and confirmed using the regulatable MYCN expression system (SHEP Tet21N).
RESULTS: MYCN knockdown altered the expression of several cell cycle related genes. SKP2 was down regulated in both cell lines, and up regulated in MYCN+ Tet21N cells. Expression of the WNT antagonist DKK3 increased in both cell lines and decreased in MYCN+ Tet21N cells. Expression of CDKN1C (p57(cip2)) and TP53INP1 also increased after MYCN knockdown.
CONCLUSIONS: MYCN may override the G1 checkpoint through down-regulation of SKP2 and TP53INP1 resulting in reduced p21(WAF1) expression in p53 wt cell lines, and in addition may act through the WNT signaling pathway in a p53 independent manner.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17495526     DOI: 10.4161/cc.6.10.4222

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  18 in total

1.  Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.

Authors:  Marco Kramer; Diogo Ribeiro; Marie Arsenian-Henriksson; Thomas Deller; Hermann Rohrer
Journal:  J Neurosci       Date:  2016-10-05       Impact factor: 6.167

2.  N-myc alters the fate of preneoplastic cells in a mouse model of medulloblastoma.

Authors:  Jessica D Kessler; Hiroshi Hasegawa; Sonja N Brun; Brian A Emmenegger; Zeng-Jie Yang; John W Dutton; Fan Wang; Robert J Wechsler-Reya
Journal:  Genes Dev       Date:  2009-01-15       Impact factor: 11.361

3.  Distinct effects of calorie restriction and exercise on mammary gland gene expression in C57BL/6 mice.

Authors:  Michela Padovani; Jackie A Lavigne; Gadisetti V R Chandramouli; Susan N Perkins; J Carl Barrett; Stephen D Hursting; L Michelle Bennett; David Berrigan
Journal:  Cancer Prev Res (Phila)       Date:  2009-12-01

4.  Identification of multiple hypoxia signatures in neuroblastoma cell lines by l1-l2 regularization and data reduction.

Authors:  Paolo Fardin; Andrea Cornero; Annalisa Barla; Sofia Mosci; Massimo Acquaviva; Lorenzo Rosasco; Claudio Gambini; Alessandro Verri; Luigi Varesio
Journal:  J Biomed Biotechnol       Date:  2010-06-28

5.  Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma.

Authors:  Rhamy Zeid; Matthew A Lawlor; Evon Poon; Jaime M Reyes; Mariateresa Fulciniti; Michael A Lopez; Thomas G Scott; Behnam Nabet; Michael A Erb; Georg E Winter; Zoe Jacobson; Donald R Polaski; Kristen L Karlin; Rachel A Hirsch; Nikhil P Munshi; Thomas F Westbrook; Louis Chesler; Charles Y Lin; James E Bradner
Journal:  Nat Genet       Date:  2018-01-29       Impact factor: 38.330

Review 6.  Targeting prostate cancer based on signal transduction and cell cycle pathways.

Authors:  John T Lee; Brian D Lehmann; David M Terrian; William H Chappell; Franca Stivala; Massimo Libra; Alberto M Martelli; Linda S Steelman; James A McCubrey
Journal:  Cell Cycle       Date:  2008-06-16       Impact factor: 4.534

Review 7.  Neuroblastoma and MYCN.

Authors:  Miller Huang; William A Weiss
Journal:  Cold Spring Harb Perspect Med       Date:  2013-10-01       Impact factor: 6.915

8.  Myc proteins as therapeutic targets.

Authors:  W C Gustafson; W A Weiss
Journal:  Oncogene       Date:  2010-01-25       Impact factor: 9.867

9.  p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.

Authors:  Lindi Chen; Deborah A Tweddle
Journal:  Front Oncol       Date:  2012-11-28       Impact factor: 6.244

10.  MYCN-mediated transcriptional repression in neuroblastoma: the other side of the coin.

Authors:  Samuele Gherardi; Emanuele Valli; Daniela Erriquez; Giovanni Perini
Journal:  Front Oncol       Date:  2013-03-11       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.